Merck stock skidded Tuesday — while also buoying Exelixis — after the Dow Jones pharma outlet said a triple approach to ...

Merck heads into Q1 with strong Keytruda demand but rising pressure from generics, vaccines slump, and deal costs persist.

Merck stock overview after recent performance moves Merck (MRK) has drawn fresh investor attention after a mixed stretch in ...

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place ...

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

If you're at all interested in the pharmaceutical sector, you may be overwhelmed by the opportunity for GLP-1 weight-loss therapies. Sure, that's an important new drug category, but it isn't the only ...

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained bullish momentum. The 50-day moving average is a short-term ...

It is no secret that the pharmaceutical industry is facing a super-cliff of patent expirations, Merck & Co., Inc.

I expect 2026 to be a transition year with AEPS decline for Merck KGaA, but I see robust growth potential beyond. Read why ...

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...